M. González Díaz

Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype.

J. S. San Miguel, M. D. del Carmen, R. García-Sanz, 1998, Haematologica.

The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome

A. Órfão, I. Criado, A. Sarmento-Ribeiro, 2021, Frontiers in Oncology.

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

K. Stamatopoulos, D. Rossi, G. Gaidano, 2018, Leukemia.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

A. Hagenbeek, G. Salles, F. d'Amore, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

F. Bosch, E. Montserrat, E. González-Barca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

N. Puig, A. Oriol, L. Corchete, 2017, Hematological oncology.